What are the side effects of Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf)?

Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) contains two active substances, pertuzumab and trastuzumab, which are already authorized for the treatment of early-stage and metastatic HER2-positive breast cancer and can be administered by intravenous infusion. Phesgo is as effective at treating breast cancer as the drug alone given intravenously. Because it is administered under the skin, it may be more convenient for patients and less invasive and faster than administration by infusion. Aside from injection site reactions, Phesgo's side effects are similar to those seen with infused pertuzumab and trastuzumab, but its benefits outweigh its risks.

The most common side effects in Phesgo's clinical studies can include hair loss, diarrhea, nausea, anemia (low red blood cell count), weakness and joint pain. The most common serious side effects include neutropenia (low white blood cell count) with or without fever, heart failure (when the heart cannot pump blood properly), fever, blood or lung infection (sepsis, pneumonia) and decreased neutrophil (a type of white blood cell) count. PhesgoAfter being launched on the market, adverse events such as glomerulopathy, immune thrombocytopenia, and tumor lysis syndrome(TLS) have occurred.

The original Phesgo drug is not marketed in the country and therefore cannot be included in medical insurance. Since Phesgo's original drug has been on the market overseas for a short time, there is less price and other related information. For specific prices and drug information, please consult Yaode's medical consultant.